Roche

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Roche poised to buy MASH drug developer 89bio for $3.5bn

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Ametris starts obesity digital endpoint project with pharma

Ametris launches a collaboration with pharma companies that aims to show how digital endpoints can be used in obesity trials.

News

OMass attracts $420m Roche wager on IBD programme

UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.

News

Roche breaks ground on US manufacturing facility

Roche's Genentech unit has started work on a $700m manufacturing facility in North Carolina, part of a promised $50bn US investment programme.

Jazz, Roche combo cleared by FDA for lung cancer

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche poised to buy MASH drug developer 89bio for $3.5bn

Ametris starts obesity digital endpoint project with pharma

OMass attracts $420m Roche wager on IBD programme

Roche breaks ground on US manufacturing facility

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks